molecular diagnostics, led by the Truenat platform.

Strengths Truenat is a portable real-time PCR platform designed for point-of-care testing and multiple infectious diseases. Installed base of roughly 12,500 devices across 90+ countries, creating a recurring consumables opportunity. Test-kit consumption is a major revenue driver; around 62.4 lakh kits were sold in Q1 FY27. Weaknesses Revenue can be non-linear and volatile because public-health programmes and government orders can shift between quarters. Management specifically highlighted this characteristic. International expansion requires continued investment in sales and market development. Dependence on the Truenat ecosystem creates concentration around one major technology platform. New products and overseas businesses require regulatory approvals and commercial ramp-up. Q1 FY27 revenue from operations was about ₹408 Cr, while consolidated debt stood around ₹413 Cr at FY26-end according to third-party financial data. Opportunities Expansion of TB testing across underserved diagnostic centres. Potential growth from HPV screening, with management discussing rollout following validation/approval processes. International expansion across the US, Europe and other emerging markets. Growth in recurring test-kit consumption as the installed device base increases. OptraScan provides an additional digital pathology/diagnostics opportunity; management expects more meaningful contribution beyond FY27. Expansion into additional infectious-disease assays and decentralised healthcare. Threats Competition from global molecular-diagnostics companies. Regulatory and product-approval risks in international markets. Government procurement and public-health programme changes can affect quarterly revenue. Pricing pressure on diagnostic kits. Rapid technological developments could require continuous R&D investment. Customer/geographic concentration could increase earnings volatility.